ABOUT THE EVENT
Date: Wednesday, October 28, 2026 11am–12pm EDT
Event Location: Virtual
Antibody-drug conjugates (ADCs) have transitioned from a “technology validation phase” into a “scale-up and commercialization phase.” The global ADC market grew from approximately USD 10.4 billion in 2023 to USD 18.5 billion in 2025, with a CAGR exceeding 30%, while next-generation ADCs like bispecific and dual-payload ADCs continue to advance.
At the same time, the competitive focus extends beyond differentiated molecular design to process robustness, manufacturing capacity, and supply chain security. Full-cycle CMC capability is becoming a key determinant of whether an ADC can successfully reach the market.
Drawing on nearly a decade of hands-on experience in ADC process development and industrialization, together with AsymBio’s experience delivering one-stop CMC services this webinar will review key ADC process challenges and advances in conjugation technology. The session will offer both strategic perspectives and practical insights spanning process development through commercial manufacturing.
Key Learning Objectives
- Identify challenges in scaling ADC manufacturing.
- Explore conjugation advances for complex ADCs.
- Understand CMC needs across development, manufacturing, and supply chains.
